1480 64th St
6 articles about Totus Medicines
Totus Medicines, the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board.
Totus Medicines today announced its participation at this year's Future of R&D Week in Boston from October 3-5.
Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors
Totus Medicines announced today the dosing of the first patient in a Phase 1 clinical trial of TOS-358, the company's first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.
Totus Medicines Announces Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Totus Medicines announced it will be presenting four posters at the American Association for Cancer Research (AACR) Annual Meeting, regarding its lead program, TOS-358, the first highly specific, covalent PI3Kα inhibitor.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
Totus Medicines Announces Poster Presentation for TOS-358, the First Highly Selective Covalent Molecule Targeting PI3Kα, at the 34th EORTC-NCI-AACR Symposium in Barcelona
Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced yesterday the poster presentation for TOS-358 at the 34th EORTC-NCI-AACR Symposium (ENA 2022) held in Barcelona Oct 26-28, 2022.